Do you want to read an article? Please log in or register.
Empagliflozin for Patients with Presumed Resistant Hypertension: a Post Hoc Analysis of the EMPA-REG OUTCOME Trial
Hypertension
Related content
Cardiovascular Risk and Diseases
Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
J Am Heart Assoc.
Waijer SW, Xie D, Inzucchi SE, Zinman B, Koitka-Weber A, Mattheus M, von Eynatten M, Inker LA, Wanner C, Heerspink HJL
doi: 10.1161/JAHA.120.016976.
Atrial FibrillationHeart Failure
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial
Eur J Heart Fail.
Böhm M, Slawik J, Brueckmann M, Mattheus M, George JT, Ofstad AP, Inzucchi SE, Fitchett D, Anker SD, Marx N, Wanner C, Zinman B, Verma S
doi: 10.1002/ejhf.1663.
Cardiovascular Risk and Diseases
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial
Eur Heart J.
Fitchett D, Inzucchi SE, Wanner C, Mattheus M, George JT, Vedin O, Zinman B, Johansen OE
doi: 10.1093/eurheartj/ehz621.
Heart Failure
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial
ESC Heart Fail
Fitchett D, Inzucchi SE, Zinman B, Wanner C, Schumacher M, Schmoor C, Ohneberg K, Ofstad AP, Salsali A, George JT, Hantel S, Bluhmki E, Lachin JM, Zannad F
doi: 10.1002/ehf2.13615
RECOMMENDED
Hypertension
Clinic Versus Ambulatory Blood Pressure in Resistant Hypertension: Impact of Antihypertensive Medication Nonadherence: A Post Hoc Analysis the DENERHTN Study
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Hypertension.
Hamdidouche I, Gosse P, Cremer A, Lorthioir A, Delsart P, Courand PY, Denolle T, Halimi JM, Girerd X, Ormezzano O, Rossignol P, Pereira H, Azizi M, DENERHTN Investigators.
doi: 10.1161/HYPERTENSIONAHA.119.13520.
Heart Failure
Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME
ESC Heart Fail.
Pellicori P, Ofstad AP, Fitchett D, Zeller C, Wanner C, George J, Zinman B, Brueckmann M, Lindenfeld J
doi: 10.1002/ehf2.12891.
Atrial FibrillationThrombosis and StrokeTherapy and Intervention
Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial
BMJ.
Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, Lanas F, Xavier D, Husted S, Wallentin L, Alexander JH, Granger CB, Verheugt FW
doi: 10.1136/bmj.i2868.
Heart Failure
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial
JAMA Cardiol
Felker GM, Solomon SD, Claggett B, Diaz R, McMurray JJV, Metra M, Anand I, Crespo-Leiro MG, Dahlström U, Goncalvesova E, Howlett JG, MacDonald P, Parkhomenko A, Tomcsányi J, Abbasi SA, Heitner SB, Hucko T, Kupfer S, Malik FI, Teerlink JR
doi: 10.1001/jamacardio.2021.4027
Heart Failure
Use of diuretics and outcomes in patients with type 2 diabetes: Findings from the EMPA-REG OUTCOME trial
Eur J Heart Fail
Pellicori P, Fitchett D, Kosiborod M, Ofstad AP, Seman L, Zinman B, Zwiener I, Wanner C, George J, Inzucchi SE, Testani J, Cleland JGF
doi: 10.1002/ejhf.2220